Skip to main
  1. Stocks
  2. Lexeo Therapeutics Inc
  3. Forecast
LXEO

LXEO Stock Forecast & Price Target

LXEO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lexeo Therapeutics is attractive because LX2006 targets the underlying frataxin deficiency driving lethal FA cardiomyopathy, a setting with no approved therapy for the cardiac manifestations and an estimated ~5,000 U.S. FA patients. The bullish case is strengthened by Phase 1/2 evidence showing LVMI reductions in all 6 patients with abnormal baseline LVMI, including ~18% at 6 months and ~28% in the mid- and high-dose cohorts, while Monte Carlo work suggests >99% of simulated SUNRISE-FA 2 trials reach the ≥15% LVMI threshold. Beyond LX2006, the 4Q26 LX2020 update, the 2H27 pivotal readout, and a modeled ~30%/~10% market value assigned to FA and PKP2-ACM respectively imply meaningful upside from a pipeline still underappreciated by the Street.

Bears say

Lexeo Therapeutics is viewed negatively because its AAV-based gene therapies remain exposed to major safety and efficacy uncertainty, including serious adverse events, immune responses, off-target effects, and the fact that only early data are available for its corrective effect. The company also faces stringent FDA scrutiny that could require additional studies or longer, more capital-intensive pivotal trials, which may force future equity issuance at less attractive valuations and strain its financing profile. Even if approved, commercial adoption could be limited by payer resistance, high treatment costs, and competition from more convenient small-molecule alternatives, while multiple programs may dilute the market potential of its pipeline.

LXEO has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

LXEO Analyst Forecast & Price Prediction

Get the latest LXEO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LXEO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexeo Therapeutics Inc (LXEO) Forecast

Analysts have given LXEO a Buy based on their latest research and market trends.

According to 6 analysts, LXEO has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexeo Therapeutics Inc (LXEO)


LXEO Analyst Forecast & Price Prediction

Get the latest LXEO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LXEO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LXEO stock data and trends